On 15 MAY Bristol-Myers Squibb Co (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The stock currently has a dividend yield of 2.8%. BMY has a PE ratio of 30.1. Currently there are 11 analysts that rate Bristol-Myers Squibb Company a buy, 2 analysts rate it a sell, and 5 rate it a hold. Bristol-Myers Squibb Co (NYSE:BMY) net profit margin is 17.70% and weekly performance is 0.02%. On last trading day company shares ended up $48.79. Analysts mean target price for the company is $54.76. Bristol-Myers Squibb Co (NYSE:BMY) distance from 50-day simple moving average (SMA50) is -3.84%.
On 13 MAY Express Scripts Holding Company (NASDAQ:ESRX) reported $0.99 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.01 by $0.02. The company had revenue of $23.69 billion for the quarter, compared to the consensus estimate of $23.81 billion. During the same quarter in the previous year, the company posted $0.99 earnings per share. The company’s revenue for the quarter was down 9.0% on a year-over-year basis. Express Scripts Holding Company (NASDAQ:ESRX) shares fell -0.16% in last trading session and ended the day on $70.14. ESRX Gross Margin is 7.80% and its return on assets is 4.00%. Express Scripts Holding Company (NASDAQ:ESRX) quarterly performance is -5.66%.
On 14 MAY MannKind Corporation (NASDAQ:MNKD) has developed a product called AFREZZA for the delivery of insulin in Type 1 and Type 2 diabetic patients. The simplistic description of AFREZZA is that it’s an insulin inhaler that could render insulin injections obsolete in the future. MannKind Corporation (NASDAQ:MNKD) shares moved up 0.13% in last trading session and was closed at $7.77, while trading in range of $7.51 – $7.89. MannKind Corporation (NASDAQ:MNKD) year to date (YTD) performance is 49.42%.
On 23 MAY PTC Therapeutics, Inc. (NASDAQ:PTCT) surging after the Committee for Medicinal Products for Human CHMP use adopted a positive opinion regarding its application for conditional marketing authorization of Ataluren. PTC Therapeutics, Inc. (NASDAQ:PTCT) ended the last trading day at $20.03. Company weekly volatility is calculated as 13.94% and price to cash ratio as 2.44. PTC Therapeutics, Inc. (NASDAQ:PTCT) showed a positive weekly performance of 32.91%.
On 16 MAY Gilead Sciences, Inc. (NASDAQ:GILD) has successfully completed Sovaldi/Ledipasvir Phase 3 studies. The company expects an approval on the combination therapy by October 2014. Gilead Sciences, Inc. (NASDAQ:GILD) net profit margin is 33.50% and weekly performance is 0.17%. On last trading day company shares ended up $80.94. Analysts mean target price for the company is $100.26. Gilead Sciences, Inc. (NASDAQ:GILD) distance from 50-day simple moving average (SMA50) is 7.94%.